| Assessment Status | Rapid Review Complete |
| HTA ID | 24002 |
| Drug | Momelotinib |
| Brand | Omjjara® |
| Indication | Momelotinib (Omjjara®) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. |
| Assessment Process | |
| Rapid review commissioned | 22/01/2024 |
| Rapid review completed | 22/02/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that momelotinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. September 2024
